COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- Study tour bolsters Sino-Vietnamese youth exchanges
- China builds barrier against desert expansion
- Guizhou dismantles most small hydropower stations to help aquatic ecosystem's health
- Meeting in Wuxi to shape future of Asia-Pacific aquaculture
- Reassessing main Eastern battlefield's role vital to safeguarding peace today
- China, Myanmar, Thailand hold ministerial-level meeting on telecom and cyberspace
